Cargando…
Pan-transcriptome-based candidate therapeutic discovery for idiopathic pulmonary fibrosis
BACKGROUND: There are two US Food and Drug Administration (FDA)-approved drugs, pirfenidone and nintedanib, for treatment of patients with idiopathic pulmonary fibrosis (IPF). However, neither of these drugs provide a cure. In addition, both are associated with several drug-related adverse events. H...
Autores principales: | Wang, Yunguan, Yella, Jaswanth K., Ghandikota, Sudhir, Cherukuri, Tejaswini C., Ediga, Harshavardhana H., Madala, Satish K., Jegga, Anil G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7659024/ https://www.ncbi.nlm.nih.gov/pubmed/33167785 http://dx.doi.org/10.1177/1753466620971143 |
Ejemplares similares
-
Consensus Gene Co-Expression Network Analysis Identifies Novel Genes Associated with Severity of Fibrotic Lung Disease
por: Ghandikota, Sudhir, et al.
Publicado: (2022) -
Unsupervised gene expression analyses identify IPF-severity correlated signatures, associated genes and biomarkers
por: Wang, Yunguan, et al.
Publicado: (2017) -
Changing Trends in Computational Drug Repositioning
por: Yella, Jaswanth K., et al.
Publicado: (2018) -
Wilms Tumor 1-Driven Fibroblast Activation and Subpleural Thickening in Idiopathic Pulmonary Fibrosis
por: Gajjala, Prathibha R., et al.
Publicado: (2023) -
Inhibition of Aurora Kinase B attenuates fibroblast activation and pulmonary fibrosis
por: Kasam, Rajesh K, et al.
Publicado: (2020)